Search research articles
Contact Us
Filters
Showing results (171-180 of 200) with videos related to
Page
of 20
Sort By:
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Cell Chemical Biology
|
December 25, 2018
Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme
Yi-Jia Li, Li Du, Jianghai Wang, et al.
JCO Precision Oncology
|
February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Kanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
The Oncologist
|
May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R Parikh, Yuting He, Ted S Hong, et al.
Clinical Colorectal Cancer
|
December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Manish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.
Pleura and Peritoneum
|
December 23, 2022
Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design
Mustafa Raoof, Kevin M Sullivan, Paul H Frankel, et al.
Cancer
|
April 17, 2024
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial
Enrique Soto-Perez-de-Celis, William Dale, Vani Katheria, et al.
JAMA Oncology
|
September 30, 2021
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial
Daneng Li, Can-Lan Sun, Heeyoung Kim, et al.
The New England Journal of Medicine
|
May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W Prager, Julien Taieb, Marwan Fakih, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 200) with videos related to
Sort By:
Page
of 20
Lancet (London, England)
|
October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Cell Chemical Biology
|
December 25, 2018
Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme
Yi-Jia Li, Li Du, Jianghai Wang, et al.
JCO Precision Oncology
|
February 1, 2022
Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Kanwal Raghav, Jonathan M Loree, Jeffrey S Morris, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Filippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
The Oncologist
|
May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
Aparna R Parikh, Yuting He, Ted S Hong, et al.
Clinical Colorectal Cancer
|
December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
Manish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.
Pleura and Peritoneum
|
December 23, 2022
Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design
Mustafa Raoof, Kevin M Sullivan, Paul H Frankel, et al.
Cancer
|
April 17, 2024
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial
Enrique Soto-Perez-de-Celis, William Dale, Vani Katheria, et al.
JAMA Oncology
|
September 30, 2021
Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial
Daneng Li, Can-Lan Sun, Heeyoung Kim, et al.
The New England Journal of Medicine
|
May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Gerald W Prager, Julien Taieb, Marwan Fakih, et al.
Page
of 20